Group of HRV 3c protease mutants altered for substrate p1' site specificity
Through structural simulation and mutation technology of HRV 3C protease, the specificity of its substrate P1' site was changed, and it changed from LEVLFQ↓G to LEVLFQ↓M, which solved the residual Gly amino acid after removing the fusion tag of wild-type protease. The problem of this achieves the effect of markless removal and broadening the scope of application.
Patent Information
- Application Number
- PCT/CN2024/084348
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-29
- Filing Date
- 2024-03-28
- Publication Date
- 2024-12-05
AI Technical Summary
After removing the fusion protein tag, the wild-type HRV 3C protease causes residual Gly amino acids to be left at the N-terminus of the target protein, limiting its application scope, and its substrate specificity is strict, making it difficult to broaden its application scope.
Through structural simulation, saturation mutation and random mutation technology combined with the eYESS system, HRV 3C protease is molecularly modified to change its substrate P1' site specificity, so that it changes from LEVLFQ↓G to LEVLFQ↓M, achieving tracelessness Excising protein fusion tags.
A series of HRV 3C protease mutants were obtained, which significantly improved the cleavage activity and specificity of the substrate LEVLFQ↓M, broadened its application range, and was able to efficiently identify multiple substrates, enhancing its practical application capabilities as tool enzymes.
Smart Images

Figure CN2024084348_05122024_PF_FP_ABST
Abstract
Description
A panel of HRV 3C protease mutants with specific alterations in the substrate P1' site
[0001] The present invention claims priority to Chinese patent application No. 202310613615.0 filed with the Patent Office of China on May 29, 2023, entitled “A group of HRV 3C protease mutants with specific changes in the substrate P1' site”, the entire contents of which are incorporated by reference into the application. Technical Field
[0002] The present invention relates to a group of HRV 3C protease mutants with substrate P1' site specificity changes, belonging to the technical fields of gene engineering and enzyme engineering. Background Art
[0003] Human rhinovirus 3C (HRV 3C) protease belongs to the cysteine protease family and has a catalytic triad of His40-Glu71-Cys146. It recognizes the LEVLFQ↓G peptide sequence and cleaves between Gln and Gly with high specificity and activity. HRV 3C protease is highly active at temperatures ranging from 4 to 30°C and is therefore widely used to remove fusion protein tags. In particular, HRV 3C protease has a significant advantage in low-temperature protein purification due to its high activity [Raran-Kurussi, S., J., Cherry, S., et al., Differential temperature dependence of tobacco etch virus and rhinovirus 3C proteases. Anal Biochem. 2013, 436(2), 142-4.].
[0004] However, wild-type HRV 3C protease (wt HRV 3C-P) as a tool enzyme has strict substrate specificity. After removing the fusion protein tag, one amino acid Gly will remain at the N-terminus of the target protein, which may make the target protein immunogenic, thus greatly limiting its scope of application.
[0005] Summary of the Invention
[0006] In view of the deficiencies of the prior art, the first object of the present invention is to provide a group of HRV 3C protease mutants with specific changes in the substrate P1' site.
[0007] In order to achieve the above technical objectives, the inventors took into account that since Met is the amino acid at the start of translation of most proteins, they molecularly modified the wild-type HRV 3C protease specifically for the substrate P1' site, so that it changed from recognizing the original polypeptide sequence LEVLFQ↓G to recognizing the polypeptide sequence LEVLFQ↓M, thereby achieving the purpose of seamless removal of the protein fusion tag.
[0008] In order to change the substrate P1' site specificity of HRV 3C protease and expand its practical application range, the present inventors adopted a combination strategy of structural simulation, saturation mutagenesis and random mutation library design, and ERS optimization YESS (eYESS) system to carry out molecular modification of HRV 3C protease. The eYESS system is based on the previously published yeast ER sequestration screening (YESS) system [Yi, L., Gebhard, MC, Li, Q., et al., Engineering of TEV protease variants by yeast ER sequestration screening (YESS) of combinatorial libraries. Proc Natl Acad Sci USA 2013, 110(18), 7229-7234], which is a protein molecular modification system that can effectively perform single-cell high-throughput screening of exogenous protease mutant libraries by optimizing the endoplasmic reticulum retention signal peptide (ER retention sequence, ERS). In the eYESS system (Figure 1), a three-step screening strategy was used to molecularly modify the HRV 3C protease. First, ERS (FEHDEL) was used at the carboxyl end of the protease mutant library and its substrate end to increase the concentration and hydrolysis reaction time of the protease and its substrate in the endoplasmic reticulum, thereby increasing the probability of protease hydrolysis reaction, amplifying weak protease hydrolysis reaction signals, and preliminarily enriching enough protease mutants. Secondly, the ERS at the carboxyl end of the substrate was removed and the ERS at the protease end was retained to increase the screening pressure of the system, thereby screening for protease mutants with improved enzyme activity. Finally, by removing the ERS at the carboxyl end of the protease to further increase the screening pressure of the system, protease mutants with further improved activity were screened out. In addition, in order to improve the effectiveness of mutant library screening, the eYESS system used the Kex2 gene knockout Saccharomyces cerevisiae strain EBY100 Kex2-Construction of a mutant library can effectively prevent proteases and their substrates from being cleaved by Kex2, the major endogenous protease in the yeast secretory pathway [Li, Q., Yi, L., Hoi, KH, et al., Profiling Protease Specificity: Combining Yeast ER Sequestration Screening (YESS) with Next Generation Sequencing. ACS Chem Biol 2017, 12(2), 510-518.].
[0009] The present invention provides a set of HRV 3C protease mutants with substrate P1' site-specific alterations, wherein lysine 22, phenylalanine 25, asparagine 106, threonine 129, alanine 140, threonine 143, or glutamine 145 of wt HRV 3C-P are mutated. Specifically, the HRV 3C protease mutants are derived by making at least one of the following mutations based on the amino acid sequence of wild-type HRV 3C protease:
[0010] (1) mutating the lysine at position 22 to any one of alanine, cysteine, glycine, leucine, methionine, proline, glutamine, arginine, valine, and tryptophan;
[0011] (2) mutating phenylalanine at position 25 to valine;
[0012] (3) mutating the asparagine at position 106 to any one of cysteine, glutamic acid, phenylalanine, glycine, lysine, arginine, threonine, valine, tryptophan, and tyrosine;
[0013] (4) mutating threonine at position 129 to isoleucine;
[0014] (5) mutating alanine at position 140 to serine;
[0015] (6) mutating the threonine at position 143 to any one of alanine, phenylalanine, methionine, proline, tryptophan, and tyrosine;
[0016] (7) Mutate the glutamine at position 145 to any one of cysteine, aspartic acid, phenylalanine, histidine, methionine, threonine, tryptophan, and tyrosine.
[0017] It should be noted that the amino acid sequence of the wild-type HRV 3C protease (wt HRV 3C-P) is shown in SEQ ID NO.1.
[0018] In one embodiment of the present invention, the HRV 3C protease mutant is obtained by mutating the lysine at position 22 of wt HRV 3C-P to methionine, the asparagine at position 106 to threonine, the threonine at position 143 to proline, and the glutamine at position 145 to threonine, to obtain the optimal mutant A3 in the first step of screening, the amino acid sequence of which is shown in SEQ ID NO.2, and the mutation sites of the remaining mutants are shown in Table 1.
[0019] In another embodiment of the present invention, the HRV 3C protease mutant is obtained by mutating the lysine at position 22 of wt HRV 3C-P to leucine, the phenylalanine at position 25 to valine, the asparagine at position 106 to tyrosine, the threonine at position 143 to methionine, and the glutamine at position 145 to methionine, to obtain the optimal mutant B22 in the second step of screening, the amino acid sequence of which is shown in SEQ ID NO.3, and the mutation sites of the remaining mutants are shown in Table 1.
[0020] In another embodiment of the present invention, the HRV 3C protease mutant is obtained by mutating the lysine at position 22 of wt HRV 3C-P to leucine, the phenylalanine at position 25 to valine, the asparagine at position 106 to tyrosine, the threonine at position 129 to isoleucine, the threonine at position 143 to methionine, and the glutamine at position 145 to methionine, to obtain the optimal mutant C3 in the third step of screening, the amino acid sequence of which is shown in SEQ ID NO.4, and the mutation sites of the remaining mutants are shown in Table 1.
[0021] Secondly, the present invention also provides genes encoding the mutants A3, B22, and C3, the nucleotide sequences of which are shown in SEQ ID NOs. 5-7.
[0022] Third, the present invention also provides a recombinant plasmid containing the gene. In one embodiment of the present invention, the recombinant plasmid is constructed based on the pRK792 or pYSD vector.
[0023] Fourthly, the present invention also provides a genetically engineered bacterium that expresses the HRV 3C protease mutant. In one embodiment of the present invention, the genetically engineered bacterium is Escherichia coli or Saccharomyces cerevisiae.
[0024] Fifth, the present invention also provides a method for screening HRV 3C protease mutants with substrate P1' site specificity changes, wherein a library covering 6 sites with a capacity of 2.7×10 8A three-step high-throughput screening of the HRV 3C protease saturation mutant library was performed using the eYESS system against the substrate LEVLFQ↓M. The specific steps included:
[0025] 1) Based on the reported structure of HRV 3C protease (PDB: 2B0F) [Bjorndahl, TC, Andrew, LC, Semenchenko, V., et al., NMR solution structures of the apo and peptide-inhibited human rhinovirus 3C protease (Serotype 14): structural and dynamic comparison. Biochemistry 2007, 46(45), 12945-12958.], the ZDOCK program in DS was used to analyze and find that the S1' substrate binding region of HRV 3C protease was 1.5 Å away from the substrate (LEVLFQ↓G)P1' site. The six amino acids of the 5′-threonine residues were Lys22, Phe25, Asn106, Thr143, Gly144, and Gln145 (Figure 2). Finally, a 2.7×10 8 A library of HRV 3C protease saturation mutants;
[0026] 2) Using the wt HRV 3C-P gene as a template, designed mutant primers containing a combination of degenerate codons NNS, NDT, VMA, ATG, and TGG were used for PCR;
[0027] 3) The PCR product obtained in step 2) was recovered on a 0.8% agarose gel and mixed with the pYSD-GAL1-Aga2-FLAG-LEVLFQ↓M-HA-FEHDEL vector, which had been double-digested with restriction endonucleases PstⅠ and EcoRI, at a molar ratio of 3:1, and then electroporated into Saccharomyces cerevisiae EBY100. Kex2- Competent cells were used to obtain a HRV 3C protease saturation mutant library containing 6 mutation sites;
[0028] 4) The constructed HRV 3C protease mutant library was cultured and induced, then fluorescently labeled with Anti-HA-FITC and Anti-FLAG-iFluor 647 antibodies. Finally, three rounds of high-throughput screening were performed using flow cytometry, focusing on yeast cells with high iFluor 647 and low FITC fluorescence signals. Yeast cells from the final round of screening were plated on YNB-CAA-Glucose plates, and single colonies were grown. Fifty individual colonies were then selected for activity and sequence analysis. The results showed that most mutants could cleave the new substrate, with the A3 mutant showing the highest activity, with a cleavage efficiency of 84.2% against the substrate LEVLFQ↓M (Figure 3).
[0029] 5) The yeast cell plasmid from the last round of screening was extracted and used as a template to amplify the protease gene. The plasmid was then mixed with the pYSD-GAL1-Aga2-FLAG-LEVLFQ↓M-HA vector digested with PstⅠ and EcoRI at a molar ratio of 3:1 and electroporated into Saccharomyces cerevisiae EBY100. Kex2- In competent cells, a library of protease mutants for the second step of screening was obtained. In this library, the screening pressure of the second step of screening was reduced by removing the ERS at the substrate end. After three rounds of flow cytometry screening, yeast cells with high iFluor 647 and low FITC fluorescence signals were obtained. Similarly, the activity and sequence of the 50 protease mutants in the last round of screening cells were analyzed, and a protease mutant B22 with the strongest cleavage activity against the substrate LEVLFQ↓M was identified. In order to verify whether the B22 mutant can maintain this cleavage efficiency under conditions without ERS, the B22 protease gene was constructed on the vector pYSD-GAL1-Aga2-FLAG-LEVLFQ↓M-HA, and its activity was detected using the YESS system. It was found that its cleavage efficiency against the substrate LEVLFQ↓M dropped from the original 95% to 50% (Figure 3). This shows that the activity of the B22 mutant needs to be further improved;
[0030] 6) To further increase the screening pressure of the system, the present invention removed the ERS at the carboxyl terminus of the protease in the third screening step. Using the B22 gene as a template, the protease mutant DNA fragment was amplified by error-prone PCR and then mixed with the pYSD-GAL1-Aga2-FLAG-LEVLFQ↓M-HA vector, which had been double-digested with PstⅠ and EcoRI, at a molar ratio of 3:1, and then electroporated into the Saccharomyces cerevisiae EBY100. Kex2-Competent cells were used to generate a library of protease mutants screened in the third step. Three rounds of sorting were then performed targeting yeast cells with high iFluor 647 and low FITC fluorescence signals. The activity and sequence of 50 mutants from the final round of screening were analyzed, leading to the identification of a mutant, C3, with the highest activity against the substrate LEVLFQ↓M, achieving a cleavage efficiency of 98% in the absence of ERS (Figure 3).
[0031] Sixth, the present invention also provides a method for detecting the kinetic parameters of HRV 3C protease and its mutants, which specifically comprises the following steps:
[0032] 1) PCR cloning was used to obtain LEVLFQ↓X-6His-GFP (X is any one of the 20 amino acids), LEVLFQ↓G-6His-wt HRV 3C-P, and LEVLFQ↓M-6His-C3 gene fragments. These fragments were then ligated into the pRK792 vector, which had been double-digested with restriction endonucleases Nco I and Xho I. The ligation products were transformed into competent Escherichia coli XL-GOLD (Invitrogen) cells. Colony PCR verification and sequencing confirmed the recombinant plasmids pRK792-MBP-LEVLFQ↓X-6His-GFP (X is any one of the 20 amino acids), pRK792-MBP-LEVLFQ↓G-6His-wt HRV 3C-P, and pRK792-MBP-LEVLFQ↓M-6His-C3, respectively.
[0033] 2) The above plasmids were transformed into BL21(DE3) competent cells to obtain E. coli expression strains containing wt HRV 3C-P and its mutants or MBP-LEVLFQ↓X-6His-GST (X is any one of 20 amino acids) fusion protein substrates;
[0034] 3) The different E. coli expression strains were cultured in LB medium (containing Amp antibiotics), and then IPTG was used to induce the expression of HRV 3C protease, its mutants, and fusion protein substrates;
[0035] 4) Purifying the HRV 3C protease, its mutants, and fusion protein substrates using Ni-NTA His resin;
[0036] 5) The purified protease was reacted with substrate at different concentration ratios. The reaction solutions at 0, 5, 10, 15, 25, and 45 min were collected and analyzed for fluorescence intensity of the GFP fusion protein on the protein gel using SDS-PAGE and a multifunctional laser analyzer. The cleavage efficiency and kinetic parameters of the HRV 3C protease mutant against different fusion protein substrates were calculated (Table 2).
[0037] Seventh, the present invention also provides a method for detecting the specificity of HRV 3C protease mutant C3 for substrate P1' site, which specifically comprises the following steps:
[0038] 1) The C3, C3-FEHDEL, Aga2-FLAG-LEVLFQ↓X-HA, and Aga2-FLAG-LEVLFQ↓X-HA-FEHDEL (X is any of the 20 amino acids) gene fragments were obtained by PCR cloning.
[0039] 2) The C3 and C3-FEHDEL PCR products obtained in step 1) were double-digested with the restriction endonucleases BamHI and XhoI, recovered from an agarose gel, and then ligated to the pYSD vector, which had been double-digested with the restriction endonucleases BamHI and XhoI. The ligated products were transformed into competent Escherichia coli XL-GOLD (Invitrogen) cells, and recombinant plasmids pYSD-GAL10-C3 and pESD-GAL10-C3-FEHDEL were obtained after colony PCR verification and sequencing confirmation, respectively.
[0040] 3) The Aga2-FLAG-LEVLFQ↓X-HA and Aga2-FLAG-LEVLFQ↓X-HA-FEHDEL PCR products obtained in step 1) were double-digested with restriction endonucleases PstI and EcoRI, recovered from an agarose gel, and then ligated with pYSD-GAL10-C3 and pYSD-GAL10-C3-FEHDEL vectors, respectively, which had been double-digested with restriction endonucleases PstI and EcoRI. The ligated products were transformed into competent Escherichia coli XL-GOLD (Invitrogen) cells, and recombinant plasmids pYSD-C3-GAL10-GAL1-Aga2-FLAG-LEVLFQ↓X-HA and pYSD-FEHDEL-C3-GAL10-GAL1-Aga2-FLAG-LEVLFQ↓X-HA, respectively, were obtained after colony PCR verification and sequencing confirmation.
[0041] 4) The above plasmids were transformed into Saccharomyces cerevisiae EBY100 Kex2- In competent cells, a Saccharomyces cerevisiae expression strain containing both HRV 3C protease mutant C3 and its substrate was obtained;
[0042] 5) The different Saccharomyces cerevisiae expression strains were cultured in YNB-CAA-Glucose medium, and then switched to YNB-CAA-Galactose medium to induce the expression of HRV 3C protease mutant C3 and its substrate.
[0043] 6) The induced yeast cells were labeled with Anti-HA-FITC and Anti-FLAG-iFlor647 fluorescent antibodies, and the fluorescence of the yeast cells was detected by flow cytometry. Finally, the cleavage efficiency of the C3 mutant against different substrates was calculated.
[0044] [Corrected 17.04.2024 according to Rule 91] Analysis results showed that when both the protease and substrate ends contained FEHDEL, the C3 mutant was able to cleave 20 substrates with cleavage efficiencies of 80%-99% (Figure 4). When the ERS at both the protease and substrate ends were removed, the C3 mutant was also able to cleave 20 substrates, albeit with varying cleavage efficiencies. Analysis revealed that the C3 mutant had a weaker cleavage efficiency of only 10%-40% for substrates containing charged or aromatic amino acids such as Asp, Glu, Phe, His, Lys, Pro, Arg, Val, Trp, and Tyr at the P1' site (Figure 5). Compared to the previously verified wild-type HRV 3C protease, which only cleaved the substrate LEVLFQ↓G when lacking ERS, the C3 mutant screened by the present invention exhibits broad substrate specificity for the P1' site, broadening the practical application of HRV 3C protease as a tool enzyme.
[0045] Compared with the prior art, the present invention has the following beneficial effects:
[0046] (1) The present invention utilizes a combination strategy of structural simulation, saturation mutagenesis, random mutagenesis technology, and the eYESS system to molecularly modify wt HRV 3C-P, changing its recognition of the original polypeptide sequence LEVLFQ↓G to the polypeptide sequence LEVLFQ↓M, thereby obtaining a series of HRV 3C protease mutants.
[0047] (2) Compared with wt HRV 3C-P, the group of HRV 3C protease mutations with substrate P1' site specificity provided by the present invention have better specificity and cleavage activity against the substrate LEVLFQ↓M, and can achieve the effect of scarless excision of protein fusion tags. BRIEF DESCRIPTION OF THE DRAWINGS
[0048] Figure 1: An eYESS system for protease molecular engineering.
[0049] Figure 2: Molecular docking diagram of wild-type HRV 3C protease and substrate LEVLFQ↓G.
[0050] The yellow area shows the substrate binding pocket of HRV 3C protease (grey). The substrate LEVLFQ↓G is shown in blue, and the Gln at the P1 site and the Gly at the P1' site are represented by blue spheres. The catalytic triad His40-Glu71-Cys146 is shown in green. In the S1 substrate binding pocket, the Gln at the P1 site forms an H bond with Thr141 and His160, respectively (red, left). In the S1' substrate binding pocket, the Gly at the P1' site is 100 mM away from the substrate. The amino acids involved are Lys22, Phe25, Asn106, Thr143, Gly144, and Gln145, represented by pink spheres (right).
[0051] Figure 3: Schematic diagram of high-throughput screening of the HRV 3C protease mutant library.
[0052] In the first screening step, both the HRV 3C protease mutant library and its substrates contained ERS at the carboxyl terminus. In the second step, the substrate carboxyl-terminal ERS was removed, while the protease-terminal ERS was retained. In the third step, both the protease-terminal and substrate-terminal ERS were removed. Throughout the yeast cell screening process, three rounds of isolation and enrichment were performed, targeting cells with high iFluor647 fluorescence and low FITC fluorescence signals. The ERS was FEHDEL.
[0053] Figure 4: Substrate P1' site specificity analysis of C3 mutants under dual ERS conditions.
[0054] Figure 5: Analysis of substrate P1' site specificity of C3 mutants under ERS-free conditions. DETAILED DESCRIPTION
[0055] The technical solutions and principles of the present invention are described below in conjunction with the accompanying drawings. The examples given are only used to explain the present invention and are not intended to limit the scope of the present invention. The experimental methods used in the following examples are conventional methods unless otherwise specified. The materials, reagents, etc. used in the following examples, unless otherwise specified, can all be obtained from commercial sources.
[0056] Example 1: Construction of a HRV 3C protease mutant library
[0057] 26 primers were designed, using the HRV 3C protease gene as a template to amplify four short fragments. Overlapping PCR was then used to assemble the HRV 3C protease gene, the ERS (FEHDEL) gene, and a 40 bp homologous sequence to the vector. The primer sequences are as follows:
[0058] F1: ATATACCTCTATACTTTAACGTCAAGGAGAAAAAACCCCGGATCCATGCAGTTACTTCG
[0059] R1:GATGTGGTAATAGTCATGATATTC
[0060] F2-1:GAATATCATGACTATTACCACATCTNNKGGTGAANDTACTGGCTTGGGTATTCATGAC
[0061] F2-2:GAATATCATGACTATTACCACATCTNNKGGTGAAVMAACTGGCTTGGGTATTCATGAC
[0062] F2-3:GAATATCATGACTATTACCACATCTNNKGGTGAAATGACTGGCTTGGGTATTCATGAC
[0063] F2-4:GAATATCATGACTATTACCACATCTNNKGGTGAATGGACTGGCTTGGGTATTCATGAC
[0064] R2:GAATGAACAACCAAAGTAGCATCAAC
[0065] F3:GTTGATGCTACTTTGGTTGTTCATTCTNNKAATTTTACTAATACTATTTTAG
[0066] R3:TTTAGTAGCGTAATCGTAACG
[0067] F4-1:CGTTACGATTACGCTACTAAANDTNNKNDTTGTGGTGGTGTTTTGTGTGC
[0068] F4-2:CGTTACGATTACGCTACTAAANDTNNKVMATGTGGTGGTGTTTTGTGTGC
[0069] F4-3:CGTTACGATTACGCTACTAAANDTNNKATGTGTGGTGGTGTTTTGTGTGC
[0070] F4-4:CGTTACGATTACGCTACTAAANDTNNKTGGTGTGGTGGTGTTTTGTGTGC
[0071] F4-5:CGTTACGATTACGCTACTAAAVMANNKNDTTGTGGTGGTGTTTTGTGTGC
[0072] F4-6:CGTTACGATTACGCTACTAAAVMANNKVMATGTGGTGGTGTTTTGTGTGC
[0073] F4-7:CGTTACGATTACGCTACTAAAVMANNKATGTGTGGTGGTGTTTTGTGTGC
[0074] F4-8:CGTTACGATTACGCTACTAAAVMANNKTGGTGTGGTGGTGTTTTGTGTGC
[0075] F4-9:CGTTACGATTACGCTACTAAAATGNNKNDTTGTGGTGGTGTTTTGTGTGC
[0076] F4-10:CGTTACGATTACGCTACTAAAATGNNKVMATGTGGTGGTGTTTTGTGTGC
[0077] F4-11:CGTTACGATTACGCTACTAAAATGNNKATGTGTGGTGGTGTTTTGTGTGC
[0078] F4-12:CGTTACGATTACGCTACTAAAATGNNKTGGTGTGGTGGTGTTTTGTGTGC
[0079] F4-13:CGTTACGATTACGCTACTAAATGGNNKNDTTGTGGTGGTGTTTTGTGTGC
[0080] F4-14:CGTTACGATTACGCTACTAAATGGNNKVMATGTGGTGGTGTTTTGTGTGC
[0081] F4-15:CGTTACGATTACGCTACTAAATGGNNKATGTGTGGTGGTGTTTTGTGTGC
[0082] F4-16:CGTTACGATTACGCTACTAAATGGNNKTGGTGTGGTGGTGTTTTGTGTGC
[0083] R4:TCGATTTTGTTACATCTACACTGTTGTTATCAGATCTCGAGTCACAATTCGTCGTGTTC
[0084] The above 21 degenerate primers used NNS and NDT, VMA, ATG, TGG degenerate codons (N is any nucleotide, S = G / C, D = A / G / T, V = A / C / G, M = A / C, and the four degenerate codon combinations of NDT / VMA / ATG / TGG covered 20 amino acids, which can effectively reduce the codon redundancy of the library). The three sites of Lys22, Asn106, and Gly144 used the NNK degenerate codon, and the three sites of Phe25, Thr143, and Gln145 used the four degenerate codon combinations of NDT / VMA / ATG / TGG.
[0085] For the first step of eYESS screening, the HRV 3C protease mutant DNA fragment amplified above was mixed with the pYSD-GAL1-Aga2-FLAG-LEVLFQ↓M-HA-FEHDEL vector double-digested with restriction endonucleases BamH Ⅰ and Xho Ⅰ at a molar ratio of 3:1 and then electroporated into Saccharomyces cerevisiae EBY100. Kex2- competent cells, thereby obtaining a HRV 3C protease saturation mutant library containing 6 sites.
[0086] In the second screening step of eYESS, the plasmid of the yeast cells from the last round of screening in the first step was extracted and used as a template to amplify the HRV 3C protease mutant DNA fragment containing ERS using the above primers F1 and R4. The fragment was then mixed with the pYSD-GAL1-Aga2-FLAG-LEVLFQ↓M-HA vector, which had been double-digested with the restriction endonucleases BamH Ⅰ and Xho Ⅰ, at a molar ratio of 3:1 and electroporated into Saccharomyces cerevisiae EBY100. Kex2- competent cells, thereby obtaining the HRV 3C protease mutant library for the second step screening.
[0087] The gene of the mutant B22 with the best activity obtained in the second step was used as a template and primers F1 and R5 were used for error-prone PCR (error rate of 1.0-1.5%) to amplify the HRV 3C protease mutant DNA fragment without ERS. The fragment was then mixed with the pYSD-GAL1-Aga2-FLAG-LEVLFQ↓M-HA vector double-digested with restriction endonucleases BamH Ⅰ and Xho Ⅰ at a molar ratio of 3:1 and electroporated into Saccharomyces cerevisiae EBY100. Kex2- Competent cells were used to obtain the HRV 3C protease mutant library for the third step screening. The R5 primer sequence is as follows:
[0088] R5: TCGATTTTGTTACATCTACACTGTTGTTATCAGATCTCGAGTCATTGCTTTTCAACGAA
[0089] Example 2: High-throughput screening of a library of HRV 3C protease mutants
[0090] The HRV 3C protease mutant library constructed in Example 1 was cultured in YNB-CAA-Glucose medium until OD 600 3.0-4.0, and then induced in YNB-CAA-Galactose medium, the initial OD 600 After induction at 30℃ for 12 hours, 2×10 9 Yeast cells were washed once with solution A and once with solution B, centrifuged at 3000 rpm for 2 min at 4°C, and then labeled with 0.1 μM Anti-HA-FITC and 0.1 μM Anti-FLAG-iFluor647 fluorescent antibodies.
[0091] The labeled yeast cells were centrifuged at 3000 rpm for 2 minutes and the supernatant was removed. The cells were washed once with solution B and finally resuspended in 1× PBS. Cells were sorted using a MoFloTM XDP 4 laser ultrafast sorting flow cytometer from Beckman, USA. The detection channels were FITC channel (525 / 40 nm bandpass) and APC channel (660 / 20 nm bandpass). In each round of sorting, 10 7 -10 8 Cells with high iFluor647 and low FITC fluorescence signals were selected. The enriched cells were then cultured with YNB-CAA-Glucose and induced with YNB-CAA-Galactose. After labeling with fluorescent antibodies, the cells were sorted again. After three rounds of sorting, the collected cells were plated onto YNB-CAA-Glucose solid medium.
[0092] A single colony was picked from the solid plate and inoculated into 3 mL of YNB-CAA-Glucose culture medium. The culture was shaken at 30°C until the OD 600 When the pH reached 3.0, centrifuge at 3000 rpm for 2 minutes, collect the cells, and discard the supernatant. Lyse the yeast cells with lysozyme to extract the yeast plasmid. The extracted yeast plasmid was then transformed into E. coli XL-Gold competent cells, amplified, and sequenced to obtain the sequence information of the selected HRV 3C protease mutants (Table 1).
[0093] Table 1 Mutation site information of HRV 3C protease mutants
[0094] Example 3: Construction of a Saccharomyces cerevisiae expression strain containing HRV 3C protease mutant C3 and its substrate plasmid
[0095] PCR cloning was used to obtain the C3, C3-FEHDEL, Aga2-FLAG-LEVLFQ↓X-HA, and Aga2-FLAG-LEVLFQ↓X-HA-FEHDEL (X is any of the 20 amino acids) gene fragments, respectively;
[0096] The C3 and C3-FEHDEL PCR products obtained above were each recovered on a 0.8% agarose gel and then double-digested with the restriction endonucleases BamH I and Xho I. The digestion system was as follows: BamH I, 1 μL; Xho I, 1 μL; 10× Cutsmart buffer, 5 μL. 30 μL of the recovered PCR product was added with ddH2O to a total of 50 μL. After digestion at 37°C for 5 h, the product was recovered on a 0.8% agarose gel.
[0097] The fragment was then ligated with the pYSD vector, which had been double-digested with the restriction endonucleases BamH I and Xho I. The ligation system was as follows: 1.2 μL of the digested fragment; 0.3 μL of the digested vector; 1 μL of T4 DNA ligase buffer (NEB); 0.3 μL of T4 DNA ligase (NEB); ddH2O was added to 10 μL and the ligation was incubated at 22°C for 1 hour. The ligation product was directly transformed into E. coli XL-GOLD competent cells, and recombinant plasmids pYSD-GAL10-C3 and pYSD-GAL10-C3-FEHDEL were obtained after colony PCR verification and sequencing confirmation, respectively.
[0098] The Aga2-FLAG-LEVLFQ↓X-HA and Aga2-FLAG-LEVLFQ↓X-HA-FEHDEL (X is any of the 20 amino acids) PCR products obtained above were recovered, double-digested with PstI and EcoRI, and purified on an agarose gel. The resulting products were then ligated with the pYSD-GAL10-C3 and pYSD-GAL10-C3-FEHDEL vectors, which had also been double-digested with PstI and EcoRI and purified on an agarose gel. The ligated products were transformed into E. coli XL-GOLD competent cells, and the recombinant plasmids pYSD-C3-GAL10-GAL1-Aga2-FLAG-LEVLFQ↓X-HA and pYSD-FEHDEL-C3-GAL10-GAL1-Aga2-FLAG-LEVLFQ↓X-HA were confirmed by colony PCR and sequencing.
[0099] The recombinant plasmids constructed above were transformed into Saccharomyces cerevisiae EBY100 by chemical transformation. Kex2- Then spread on YNB-CAA-Glucose plates and culture at 30℃ for 3-4 days.
[0100] Example 4: Detection of HRV 3C protease mutant activity using the YESS system
[0101] The yeast transformants transformed with HRV 3C protease mutant C3 and its substrate plasmid in Example 3 were inoculated into 1 mL of YNB-CAA-Glucose culture medium and cultured overnight at 30°C in a shaking incubator. 600 When the OD value reaches 3.0-4.0, switch to YNB-CAA-Galactose culture medium for induction, and start 600 The concentration of 10 6 Each cell was labeled with 0.1 μM Anti-HA-FITC and 0.1 μM Anti-FLAG-iFluor647 fluorescent antibodies. Detection was performed using a CytoFLEX analytical flow cytometer from Beckman, USA. The detection channels were the FITC channel (525 / 40 nm bandpass) and the APC channel (660 / 20 nm bandpass). The cleavage efficiency of the C3 mutant against different substrates was calculated as follows: [Substrate cleavage efficiency] = [Percentage of cells with only iFluor647 fluorescent signal] / ([Percentage of cells with only iFluor647 fluorescent signal] + [Percentage of cells with both iFluor647 and FITC fluorescent signals]).
[0102] The components of the culture medium and cell washing solution described in Examples 2 and 4 are as follows:
[0103] YNB-CAA-Glucose: 20g / L glucose, 6.7g / L YNB, 5.4g / L Na2HPO4, 8.6g / L NaH2PO4·H2O, 5g / L casamino acids, pH7.4;
[0104] YNB-CAA-Galactose: 20g / L galactose, 6.7g / L YNB, 5.4g / L Na2HPO4, 8.6g / L NaH2PO4·H2O, 5g / L casamino acids, pH7.4;
[0105] Solution A: 1X PBS, 0.5% BSA, 1 mM EDTA, pH 7.4;
[0106] Solution B: 1X PBS, 0.5% BSA, pH 7.4.
[0107] Example 5: Construction of E. coli expression strain containing HRV 3C protease and its substrate plasmid
[0108] PCR cloning was used to obtain the LEVLFQ↓X-6His-GFP (X is any one of the 20 amino acids), LEVLFQ↓G-6His-wt HRV 3C-P, and LEVLFQ↓M-6His-C3 gene fragments;
[0109] The PCR products were recovered on a 0.8% agarose gel and then double-digested with restriction endonucleases Nco I and Xho I. The digestion system was as follows: Nco I, 1 μL; Xho I, 1 μL; 10× Cutsmart buffer, 5 μL. 30 μL of the recovered PCR product was added with ddH2O to a total of 50 μL. After digestion at 37°C for 5 h, the product was recovered on a 0.8% agarose gel.
[0110] The fragment was then ligated with the pRK792 vector, which had been double-digested with restriction endonucleases Nco I and Xho I. The ligation system was as follows: 1.2 μL of the digested fragment; 0.3 μL of the digested vector; 1 μL of T4 DNA ligase buffer (NEB); 0.3 μL of T4 DNA ligase (NEB); ddH2O was added to 10 μL, and the ligation was incubated at 22°C for 1 h. The ligation products were directly transformed into Escherichia coli XL-GOLD competent cells. After colony PCR verification and sequencing, the recombinant plasmids pRK792-MBP-LEVLFQ↓X-6His-GFP (X is any of the 20 amino acids), pRK792-MBP-LEVLFQ↓G-6His-wt HRV 3C-P, and pRK792-MBP-LEVLFQ↓M-6His-C3 were obtained, respectively.
[0111] The recombinant plasmids constructed above were transformed into BL21 (DE3) by chemical transformation, and then spread on LB (containing ampicillin antibiotic) plates and cultured at 37°C overnight.
[0112] The PCR reaction system described in Examples 1, 3, and 5 was as follows: 10× KOD buffer, 5 μL; dNTPs (2.5 mM), 4 μL; Primer F (10 μM), 3 μL; Primer R (10 μM), 3 μL; Pfu polymerase, 2 μL; Template, 1 μL; ddH₂O added to 50 μL. PCR amplification system: 95°C, 5 min; 95°C, 30 s; 55°C, 30 s; 72°C, 30 s, 25 cycles; 72°C, 5 min; 12°C, 10 min.
[0113] Example 6: Kinetics experiments of HRV 3C protease and its mutants
[0114] The E. coli transformants transformed with HRV 3C protease and its mutants and fusion protein substrate plasmids in Example 5 were inoculated into 2 mL LB culture medium and cultured overnight at 37°C in a shaking incubator; transferred into 200 mL LB liquid culture medium (supplemented with ampicillin antibiotics) and cultured at 37°C in a shaking incubator for 2-3 h until the OD 600 To achieve a lysate of 0.6-0.8, add IPTG to a final concentration of 0.5 mM to induce protein expression and incubate at 18°C on a shaker for 20-24 hours. Collect the cells by centrifugation at 4000 rpm for 10 minutes at 4°C, discard the supernatant, and wash the cells twice with sterile water. Resuspend the cells in 20 mL of Lysis Buffer and stir at 4°C for 1 hour. Disrupt the cells by ultrasonication on ice for 2 seconds on, 4 seconds off, and 35% power for 15 minutes. Centrifuge the lysis solution at 17000 rpm at 4°C for 30 minutes to completely separate cell debris from the supernatant. Add 1 mL of Ni-NTA His resin to the protein purification column and wash the resin twice with 2 mL of Wash Buffer. Add 2 mL of the lysis supernatant to the protein purification column and let it stand for 5 minutes to release contaminants. Wash the resin with 2 mL of Wash Buffer to remove unbound proteins. Wash the resin with an equal amount of Wash Buffer after each addition of lysis supernatant until the target protein is completely bound to the column. Finally, the eluted target protein was desalted using an AKATA protein purifier and stored in Storage Buffer to remove high concentrations of imidazole to avoid affecting subsequent protein experiments.
[0115] The purified wt HRV 3C-P and its mutants (100 nM) were mixed with different concentrations of the fusion protein substrate MBP-LEVLFQ↓X-6His-GFP (5 μM, 15 μM, 30 μM, 60 μM, 120 μM, and 320 μM; X is any amino acid among A, C, G, I, L, M, N, Q, S, and T), and 20 μL of Cleavage buffer was added. The reaction was carried out at 4°C in a total reaction volume of 200 μL.
[0116] At 0, 5, 10, 15, 25, and 45 min, the reaction samples were mixed with SDS-PAGE loading buffer and boiled at 100 °C for 10 min to terminate the protease hydrolysis reaction. The samples were then analyzed by SDS-PAGE at 4 °C and the images were obtained using a multifunctional laser imager (Amersham). TMTyphoon was used to detect the fluorescence intensity of the GFP fusion protein on the protein gel image to calculate the protease hydrolysis efficiency. The calculation formula was: [Protease hydrolysis efficiency] = ([Gray intensity of the cleaved protein substrate MBP-LEVLFQ↓X-6His-GFP] / [Gray intensity of the control protein substrate MBP-LEVLFQ↓M / G-6His-GFP]) × 100%. Finally, the data were fitted with the Michaelis–Menten enzyme kinetic model to calculate the kinetic parameters (Table 2).
[0117] The protein purification reagent components are as follows:
[0118] Lysis Buffer: 50mM Tris-HCl (pH 8.0), 200mM NaCl, 50mM NaH2PO4, 25mM Imidazole, 10% Glycerol;
[0119] Wash Buffer: 50mM Tris-HCl (pH 8.0), 200mM NaCl, 50mM NaH2PO4, 40mM Imidazole;
[0120] Elution Buffer: 50mM Tris-HCl (pH 8.0), 200mM NaCl, 50mM NaH2PO4, 200mM Imidazole;
[0121] Storage Buffer: 50mM Tris-HCl (pH 7.5), 1mM EDTA;
[0122] Cleavage buffer: 150mM NaCl, 50mM Tris-HCl (pH 7.5).
[0123] Table 2 Kinetic parameters of HRV 3C protease and its mutant C3 against fusion protein substrates
[0124] The above examples show that the present invention has obtained a series of HRV 3C protease mutants with altered specificity for the substrate P1' site, among which the C3 mutant has the strongest activity against the substrate LEVLFQ↓M and has a wide substrate specificity for the substrate P1' site, capable of recognizing any 20 amino acids at the P1' site. In addition, the k-values of the C3 mutant against 10 fusion protein substrates MBP-LEVLFQ↓X-6His-GFP (X is any amino acid among A, C, G, I, L, M, N, Q, S, and T) are significantly different. cat / K MValues ranged from 0.37±0.01 to 3.72±0.04mM -1 ·s -1 The wild-type HRV 3C protease can only recognize and cleave four fusion protein substrates MBP-LEVLFQ↓X-6His-GFP (X is any amino acid among A, C, G, S), k cat / K M The values ranged from 0.39 ± 0.03 to 4.73 ± 0.01 mM -1 ·s -1 between.
Claims
1. A HRV 3C protease mutant with a substrate P1' site-specific change, characterized in that: The amino acid sequence of the HRV 3C protease mutant is obtained by performing at least one of the following mutations on the amino acid sequence of the wild-type HRV 3C protease: (1) mutating the lysine at position 22 to any one of alanine, cysteine, glycine, leucine, methionine, proline, glutamine, arginine, valine and tryptophan; (2) mutating phenylalanine at position 25 to valine; (3) mutating the asparagine at position 106 to any one of cysteine, glutamic acid, phenylalanine, glycine, lysine, arginine, threonine, valine, tryptophan and tyrosine; (4) mutating the threonine at position 129 to isoleucine; (5) mutating alanine at position 140 to serine; (6) mutating the threonine at position 143 to any one of alanine, phenylalanine, methionine, proline, tryptophan and tyrosine; (7) Mutating the glutamine at position 145 to any one of cysteine, aspartic acid, phenylalanine, histidine, methionine, threonine, tryptophan and tyrosine.
2. The HRV 3C protease mutant with substrate P1' site specificity change according to claim 1, characterized in that: The amino acid sequence of the wild-type HRV 3C protease is shown in SEQ ID NO.
1.
3. The HRV 3C protease mutant with substrate P1' site specificity change according to claim 1, characterized in that: The amino acid sequence of the HRV 3C protease mutant is shown in SEQ ID NO.2, SEQ ID NO.3 or SEQ ID NO.
4.
4. A gene encoding the HRV 3C protease mutant according to claim 1.
5. The gene according to claim 4, characterized in that The nucleotide sequence of the gene is shown in SEQ ID NO.5, SEQ ID NO.6 or SEQ ID NO.
7.
6. A recombinant plasmid containing the gene according to claim 4.
7. The recombinant plasmid according to claim 6, characterized in that The recombinant plasmid is constructed on the basis of pRK792 or pYSD plasmid.
8. A genetically engineered bacterium expressing the HRV 3C protease mutant of claim 1.
9. The genetically engineered bacterium according to claim 8, characterized in that: The genetically engineered bacteria is Saccharomyces cerevisiae or Escherichia coli.
10. A method for screening HRV 3C protease mutants with substrate P1' site specificity changes, characterized in that: The method involves constructing a library covering 6 loci with a capacity of 2.7×10 8 The HRV 3C protease saturation mutant library was screened in three steps against the substrate LEVLFQ↓M using an optimized Saccharomyces cerevisiae endoplasmic reticulum retention screening system.
Citation Information
Patent Citations
Cleavage efficiency enhanced substrate mutant of HRV (Human Rhinovirus) 3C protease and application thereof
CN107602706A
Group of HRV 3C protease mutants for specific change of substrate P1'site
CN116555235A
